Planchard D et al. -Dabrafenib plus trametinib was shown in the current study to have anti-tumour activity with a reasonable safety profile in patients with previously untreated BRAFV600E-mutant NSCLC.

Methods
Adults greater than or equal to 18 years of age with previously untreated metastatic BRAFV600E-mutant NSCLC were enrolled.
Patients received oral dabrafenib (150 mg twice per day) plus oral trametinib (2 mg once per day) until disease progression, unacceptable adverse events, consent withdrawal, or death.
The primary endpoint was investigator-assessed overall response.

Results
36 patients were enrolled and treated with first-line dabrafenib plus trametinib.
The median follow-up was 15.9 months.
23 patients achieved an overall response, with 2 achieving a complete response and 21 achieving a partial response.
All patients had one or more adverse event of any grade.